All In Biotech

Drug Trial Radar · NCT04107480

PRolaCT - Three Prolactinoma RCTs

PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials

Last checked: Nov 20, 2026Latest source record: Jul 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

880

Planned (sponsor's estimate)

Start

Jun 21, 2019

Primary completion

Mar 31, 2024

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Leiden University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate if endoscopic trans-sphenoidal prolactinoma resection as a first line treatment, or as an equally valid second line treatment after a short (4-6 months) or long (\>2 years) period of pretreatment with a dopamine agonist is superior to standard care for several outcome parameters. The main objectives are to investigate this for quality of life and remission rate. The secondary objectives are to investigate this for biochemical disease control, recurrence rates, clinical symptom control, tumor shrinkage on MRI, pituitary functioning, the occurrence of adverse reactions to treatment, disease burden, and cost-effectiveness.

Conditions

  • Prolactinoma
  • Prolactin-Producing Pituitary Tumor

Interventions

  • Endoscopic trans-sphenoidal adenoma resectionProcedure

    Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group. Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice.

  • Dopamine AgonistsDrug

    The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care. Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued. In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Health-Related Quality of LifeTime frame: 12 months after randomization/baseline
  2. Long-term remissionTime frame: 36 months after randomization/baseline

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Amsterdam University Medical Center, loc. AMC

    Amsterdam-Zuidoost, North Holland, Netherlands · Not yet recruiting

  • Reinier de Graaf Gasthuis

    Delft, South Holland, Netherlands · Not yet recruiting

  • Leiden University Medical Center

    Leiden, South Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.